131I-Lym-1 in Mice Implanted with Human Burkitt's Lymphoma (Raji) Tumors: Loss of Tumor Specificity due to Radiolysis
- 1 December 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 15 (6), 547-560
- https://doi.org/10.1089/cbr.2000.15.547
Abstract
Preliminary evaluations of 125I-labeled Lytn-1, an anti-lymphoma mouse IgG2a monoclonal antibody, demonstrated favorable tumor uptake in mice bearing human Burkitt's lymphoma (Raji) tumors. In this study, the pharmacokinetics of 125I- and 131I-Lym-1, and the dosimetry, efficacy, and toxicity of 131I-Lym-1 in Raji-tumored mice were evaluated.Keywords
This publication has 9 references indexed in Scilit:
- Stability of Monoclonal Antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 Immunoconjugate with Ultra Freezer StorageCancer Biotherapy & Radiopharmaceuticals, 1999
- Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1998
- Enhancement of67Cu-2IT-BAT-LYM-1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin-2Cancer, 1997
- Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II StudyGynecologic Oncology, 1997
- Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10Cancer Immunology, Immunotherapy, 1996
- Comparative toxicity studies of yttrium-90 mx-dtpa and 2-it-bad conjugated monoclonal antibody (bre-3)Cancer, 1994
- Processing of antibody-radioisotope conjugates after binding to the surface of tumor cellsCancer, 1994
- Multicellular dosimetry for beta‐emitting radionuclides: Autoradiography, thermoluminescent dosimetry and three‐dimensional dose calculationsMedical Physics, 1993
- A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1Cancer Biotherapy, 1993